Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease. From 2007 to 2014, Children's Oncology Group trial AALL0434 (ClinicalTrials.gov identifier:...
Saved in:
Published in | Journal of clinical oncology Vol. 38; no. 28; pp. 3282 - 3293 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society of Clinical Oncology
01.10.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease.
From 2007 to 2014, Children's Oncology Group trial AALL0434 (ClinicalTrials.gov identifier: NCT00408005) enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial randomization to receive escalating-dose methotrexate (MTX) without leucovorin rescue plus pegaspargase (C-MTX) or high-dose MTX (HDMTX) with leucovorin rescue. Intermediate- and high-risk patients were also randomly assigned after induction to receive or not receive six 5-day courses of nelarabine that was incorporated into ABFM. Patients who experienced induction failure were nonrandomly assigned to HDMTX plus nelarabine. Patients with overt CNS disease (CNS3; ≥ 5 WBCs/μL with blasts) received HDMTX and were randomly assigned to receive or not receive nelarabine. All patients, except those with low-risk disease, received cranial irradiation.
The 5-year event-free and overall survival rates were 83.7% ± 1.1% and 89.5% ± 0.9%, respectively. The 5-year disease-free survival (DFS) rates for patients with T-ALL randomly assigned to nelarabine (n = 323) and no nelarabine (n = 336) were 88.2% ± 2.4% and 82.1% ± 2.7%, respectively (
= .029). Differences between DFS in a four-arm comparison were significant (
= .01), with no interactions between the MTX and nelarabine randomizations (
= .41). Patients treated with the best-performing arm, C-MTX plus nelarabine, had a 5-year DFS of 91% (n = 147). Patients who received nelarabine had significantly fewer isolated and combined CNS relapses compared with patients who did not receive nelarabine (1.3% ± 0.63%
6.9% ± 1.4%, respectively;
= .0001). Toxicities, including neurotoxicity, were acceptable and similar between all four arms.
The addition of nelarabine to ABFM therapy improved DFS for children and young adults with newly diagnosed T-ALL without increased toxicity. |
---|---|
AbstractList | Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully evaluated in those with newly diagnosed disease.
From 2007 to 2014, Children's Oncology Group trial AALL0434 (ClinicalTrials.gov identifier: NCT00408005) enrolled 1,562 evaluable patients with T-ALL age 1-31 years who received the augmented Berlin-Frankfurt-Muenster (ABFM) regimen with a 2 × 2 pseudo-factorial randomization to receive escalating-dose methotrexate (MTX) without leucovorin rescue plus pegaspargase (C-MTX) or high-dose MTX (HDMTX) with leucovorin rescue. Intermediate- and high-risk patients were also randomly assigned after induction to receive or not receive six 5-day courses of nelarabine that was incorporated into ABFM. Patients who experienced induction failure were nonrandomly assigned to HDMTX plus nelarabine. Patients with overt CNS disease (CNS3; ≥ 5 WBCs/μL with blasts) received HDMTX and were randomly assigned to receive or not receive nelarabine. All patients, except those with low-risk disease, received cranial irradiation.
The 5-year event-free and overall survival rates were 83.7% ± 1.1% and 89.5% ± 0.9%, respectively. The 5-year disease-free survival (DFS) rates for patients with T-ALL randomly assigned to nelarabine (n = 323) and no nelarabine (n = 336) were 88.2% ± 2.4% and 82.1% ± 2.7%, respectively (
= .029). Differences between DFS in a four-arm comparison were significant (
= .01), with no interactions between the MTX and nelarabine randomizations (
= .41). Patients treated with the best-performing arm, C-MTX plus nelarabine, had a 5-year DFS of 91% (n = 147). Patients who received nelarabine had significantly fewer isolated and combined CNS relapses compared with patients who did not receive nelarabine (1.3% ± 0.63%
6.9% ± 1.4%, respectively;
= .0001). Toxicities, including neurotoxicity, were acceptable and similar between all four arms.
The addition of nelarabine to ABFM therapy improved DFS for children and young adults with newly diagnosed T-ALL without increased toxicity. |
Author | Winick, Naomi J Devidas, Meenakshi Winter, Stuart S Zweidler-Mckay, Patrick A Heerema, Nyla A Raetz, Elizabeth A Gastier-Foster, Julie M Chen, Zhiguo Dunsmore, Kimberly P Briegel, Nikki Hayashi, Robert J Carroll, Andrew J Rabin, Karen R Wood, Brent L Esiashvili, Natia Schultz, Kirk R Loh, Mignon L Asselin, Barbara L Hunger, Stephen P Eisenberg, Nancy Carroll, William L |
Author_xml | – sequence: 1 givenname: Kimberly P surname: Dunsmore fullname: Dunsmore, Kimberly P organization: Virginia Tech Carilion School of Medicine and Carilion Clinic, Roanoke, VA – sequence: 2 givenname: Stuart S surname: Winter fullname: Winter, Stuart S organization: Children's Minnesota Cancer and Blood Disorders Program, Minneapolis, MN – sequence: 3 givenname: Meenakshi surname: Devidas fullname: Devidas, Meenakshi organization: Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN – sequence: 4 givenname: Brent L surname: Wood fullname: Wood, Brent L organization: Laboratory Medicine, Seattle Children's Hospital, Seattle, WA – sequence: 5 givenname: Natia surname: Esiashvili fullname: Esiashvili, Natia organization: Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA – sequence: 6 givenname: Zhiguo surname: Chen fullname: Chen, Zhiguo organization: Department of Biostatistics, Colleges of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL – sequence: 7 givenname: Nancy surname: Eisenberg fullname: Eisenberg, Nancy organization: Pediatric Hematology/Oncology, University of New Mexico Health Sciences Center, Albuquerque, NM – sequence: 8 givenname: Nikki surname: Briegel fullname: Briegel, Nikki organization: Pharmacy Department, Perth Children's Hospital, Nedlands, Western Australia, Australia – sequence: 9 givenname: Robert J surname: Hayashi fullname: Hayashi, Robert J organization: Pediatric Hematology/Oncology, Washington School of Medicine, St Louis Children's Hospital, St Louis, MO – sequence: 10 givenname: Julie M surname: Gastier-Foster fullname: Gastier-Foster, Julie M organization: Department of Pathology, The Ohio State University, Columbus, OH – sequence: 11 givenname: Andrew J surname: Carroll fullname: Carroll, Andrew J organization: Department of Genetics, University of Alabama at Birmingham, Birmingham, AL – sequence: 12 givenname: Nyla A surname: Heerema fullname: Heerema, Nyla A organization: Department of Pathology, The Ohio State University, Columbus, OH – sequence: 13 givenname: Barbara L surname: Asselin fullname: Asselin, Barbara L organization: Department of Pediatrics, University of Rochester Medical Center and Wilmot Cancer Institute, Rochester, NY – sequence: 14 givenname: Karen R surname: Rabin fullname: Rabin, Karen R organization: Pediatric Hematology/Oncology, Baylor College of Medicine/Dan L. Duncan Comprehensive Cancer Center, Houston TX – sequence: 15 givenname: Patrick A surname: Zweidler-Mckay fullname: Zweidler-Mckay, Patrick A organization: ImmunoGen, Waltham, MA – sequence: 16 givenname: Elizabeth A surname: Raetz fullname: Raetz, Elizabeth A organization: Laura and Isaac Perlmutter Cancer Center at New York University Langone Health, New York, NY – sequence: 17 givenname: Mignon L surname: Loh fullname: Loh, Mignon L organization: Department of Pediatrics, University of California, San Francisco Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA – sequence: 18 givenname: Kirk R surname: Schultz fullname: Schultz, Kirk R organization: Pediatric Hematology-Oncology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada – sequence: 19 givenname: Naomi J surname: Winick fullname: Winick, Naomi J organization: Pediatric Hematology/Oncology, University of Texas Southwestern/Simmons Cancer Center, Dallas, TX – sequence: 20 givenname: William L surname: Carroll fullname: Carroll, William L organization: Laura and Isaac Perlmutter Cancer Center at New York University Langone Health, New York, NY – sequence: 21 givenname: Stephen P surname: Hunger fullname: Hunger, Stephen P organization: Department of Pediatrics and The Center for Childhood Cancer Research, The Children's Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32813610$$D View this record in MEDLINE/PubMed |
BookMark | eNpVkUtvEzEQxy1URNPCjTPyjQsb_NgnB6TV0pagFUEoSNysWXs2MXjtyE5A4WvwhdlSqOAyo9H8H4ffBTnzwSMhTzlbcsHYy3fdeinYkjFRlA_IgheiyqqqKM7IglVSZLyWn8_JRUpfGON5LYtH5FyKmsuSswX52e2sMxH980TXXgcXtid6E8NxT9u271ku81e0pR92kJCuViv6EbwJk_2BhnbOeqvB0U20txPTwfotfY8OIgzWI7V-vr67E31jYetDmk2brEPnaKuPB6T9adrvwuBgdmra4_ErThYek4cjuIRP_uxL8un6atO9zfr1zapr-0zLOj9kiLLJR84049AAaJ1zCTmA4LXJwTSC8aExI5Q1k9LwCmszShTQMN5gOQh5SV7f5e6Pw4RGoz9EcGof7QTxpAJY9f_H253ahm-qKkRZ8WYOeHEXoGNIKeJ47-VM3cJRMxwlmPoNZ5Y_-7fvXvyXhvwFgD2NgQ |
CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_23_0415 crossref_primary_10_1038_s41572_024_00525_x crossref_primary_10_1182_hematology_2023000512 crossref_primary_10_1111_bjh_19067 crossref_primary_10_1001_jama_2021_0669 crossref_primary_10_1182_blood_2022018653 crossref_primary_10_1007_s12185_023_03539_5 crossref_primary_10_3389_fonc_2021_750789 crossref_primary_10_1007_s12185_023_03701_z crossref_primary_10_1016_j_clml_2022_07_010 crossref_primary_10_1002_cpt_2241 crossref_primary_10_1080_10428194_2022_2102621 crossref_primary_10_1159_000533819 crossref_primary_10_1016_j_yao_2024_02_007 crossref_primary_10_1002_hon_2910 crossref_primary_10_1016_j_jtct_2022_05_037 crossref_primary_10_1111_bjh_17310 crossref_primary_10_1007_s11899_021_00640_6 crossref_primary_10_1182_blood_2023020678 crossref_primary_10_3324_haematol_2022_281926 crossref_primary_10_1007_s00280_021_04373_4 crossref_primary_10_1007_s11899_023_00706_7 crossref_primary_10_1200_JCO_21_02678 crossref_primary_10_3389_fimmu_2023_1187665 crossref_primary_10_3390_ijms23105515 crossref_primary_10_1002_pbc_31123 crossref_primary_10_1182_bloodadvances_2021004334 crossref_primary_10_1155_2022_9312971 crossref_primary_10_3390_cancers14081873 crossref_primary_10_1038_s41375_024_02277_9 crossref_primary_10_3390_cancers13092108 crossref_primary_10_1016_j_retram_2023_103431 crossref_primary_10_3390_cancers15153928 crossref_primary_10_1080_10428194_2021_1901097 crossref_primary_10_1097_MOP_0000000000001316 crossref_primary_10_1186_s13045_023_01409_5 crossref_primary_10_3390_ijms22094502 crossref_primary_10_1080_17474086_2024_2370559 crossref_primary_10_1182_hematology_2022000337C crossref_primary_10_3174_ajnr_A7692 crossref_primary_10_3390_cancers14246142 crossref_primary_10_3390_jcm10143016 crossref_primary_10_1007_s11033_022_07543_6 crossref_primary_10_1007_s00277_022_04880_1 crossref_primary_10_1016_S2152_2650_21_01225_8 crossref_primary_10_1007_s12098_023_04731_5 crossref_primary_10_1177_20406207221143025 crossref_primary_10_1002_cncr_34646 crossref_primary_10_1007_s12185_022_03501_x crossref_primary_10_1016_j_isci_2023_108171 crossref_primary_10_1016_j_beha_2023_101449 crossref_primary_10_3390_cancers14122912 crossref_primary_10_1016_j_clml_2024_06_007 crossref_primary_10_1016_S2352_3026_23_00091_1 crossref_primary_10_1158_2643_3230_BCD_20_0093 crossref_primary_10_1007_s11864_021_00860_1 crossref_primary_10_3390_cancers13164068 crossref_primary_10_3390_cancers15133346 crossref_primary_10_5863_1551_6776_29_1_53 crossref_primary_10_1080_14656566_2021_1931683 crossref_primary_10_1200_JCO_20_03370 crossref_primary_10_1080_14737140_2022_2093718 crossref_primary_10_7759_cureus_33729 crossref_primary_10_1038_s41375_021_01277_3 crossref_primary_10_1200_JCO_22_02734 crossref_primary_10_3389_fped_2022_807992 crossref_primary_10_1016_S2352_3026_23_00072_8 crossref_primary_10_1007_s11912_022_01220_4 crossref_primary_10_1200_JCO_23_01351 crossref_primary_10_1038_s41375_022_01714_x crossref_primary_10_1166_mex_2022_2185 crossref_primary_10_1182_blood_2020008471 crossref_primary_10_1182_bloodadvances_2022008280 crossref_primary_10_7759_cureus_57399 crossref_primary_10_1182_bloodadvances_2023011267 crossref_primary_10_1111_jpc_16163 crossref_primary_10_1182_blood_2020010438 crossref_primary_10_1182_bloodadvances_2022007197 crossref_primary_10_1182_hem_V18_4_2021412 crossref_primary_10_1007_s11864_024_01213_4 crossref_primary_10_1080_14737140_2023_2271662 crossref_primary_10_1053_j_seminhematol_2020_11_004 crossref_primary_10_1200_EDBK_349647 crossref_primary_10_1272_jnms_JNMS_2024_91_206 crossref_primary_10_1002_cam4_7246 crossref_primary_10_1182_blood_2022019532 crossref_primary_10_1111_bph_16029 crossref_primary_10_7759_cureus_49930 crossref_primary_10_15252_emmm_202216554 crossref_primary_10_1016_S2352_3026_23_00064_9 crossref_primary_10_1007_s00277_023_05373_5 crossref_primary_10_1182_hem_V18_6_2021613 crossref_primary_10_1002_ajh_26144 crossref_primary_10_1080_19336918_2023_2191913 crossref_primary_10_1200_JCO_23_01286 crossref_primary_10_1080_23808993_2021_1903314 crossref_primary_10_1001_jamanetworkopen_2022_48803 crossref_primary_10_1182_bloodadvances_2023010303 crossref_primary_10_1097_CCO_0000000000000900 crossref_primary_10_1016_j_blre_2024_101208 crossref_primary_10_1182_hem_V21_1_2024115 crossref_primary_10_1200_JCO_20_02973 crossref_primary_10_1182_blood_2021015108 crossref_primary_10_3390_ijms24087201 crossref_primary_10_1002_pbc_30581 crossref_primary_10_1111_bjh_19250 crossref_primary_10_1111_bjh_19492 crossref_primary_10_15421_022136 crossref_primary_10_1158_1078_0432_CCR_22_2562 crossref_primary_10_1038_s41375_022_01540_1 crossref_primary_10_1007_s11912_021_01168_x crossref_primary_10_1002_pbc_29238 crossref_primary_10_1007_s12098_023_04745_z crossref_primary_10_1080_14656566_2022_2033725 crossref_primary_10_1200_JCO_22_02430 crossref_primary_10_1097_MPH_0000000000002844 crossref_primary_10_1182_hematology_2021000224 crossref_primary_10_1200_JCO_23_00088 crossref_primary_10_1016_S2352_3026_22_00168_5 crossref_primary_10_1182_hematology_2022000337 crossref_primary_10_3390_jpm11080715 crossref_primary_10_3389_fonc_2021_631594 crossref_primary_10_1016_j_clml_2023_10_011 crossref_primary_10_1182_blood_2023023568 crossref_primary_10_1016_j_ejca_2022_08_013 crossref_primary_10_1002_pbc_30571 crossref_primary_10_3390_biomedicines9111621 crossref_primary_10_1200_OP_21_00843 |
Cites_doi | 10.1182/blood-2003-07-2577 10.1182/blood-2006-11-056754 10.1016/S1470-2045(08)70314-0 10.1200/JCO.2011.40.8724 10.1214/aos/1176350951 10.1182/blood-2011-03-338707 10.1080/01621459.1958.10501452 10.1200/JCO.1998.16.3.920 10.1111/bjh.14877 10.1002/pbc.25470 10.1111/bjh.13847 10.1182/blood.V124.21.3702.3702 10.1016/j.blre.2017.08.006 10.1056/NEJMra1400972 10.1016/j.clinthera.2007.09.002 10.1182/blood-2005-08-3482 10.1126/science.1102160 10.1038/bjc.1977.1 10.1182/blood-2007-02-070342 10.1111/bjh.12882 10.1200/JCO.2018.77.7250 10.1200/JCO.2005.03.199 10.1016/S1470-2045(15)00363-0 10.1038/leu.2016.60 10.1016/S1470-2045(12)70600-9 10.1002/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4 10.1200/JCO.2005.03.426 10.1182/blood-2015-09-670729 10.1056/NEJMoa1110169 10.1182/blood-2010-06-292615 10.1200/JCO.2011.37.8018 10.1200/JCO.2014.59.1636 10.1182/blood.V99.12.4386 10.1200/JCO.2015.62.4544 10.1016/S0037-1963(03)00195-1 10.1200/JCO.1998.16.4.1270 10.1182/blood.V124.21.21.21 |
ContentType | Journal Article |
Copyright | 2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology |
Copyright_xml | – notice: 2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM |
DOI | 10.1200/JCO.20.00256 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
DocumentTitleAlternate | Nelarabine Use in Newly Diagnosed T-Cell ALL |
EISSN | 1527-7755 |
EndPage | 3293 |
ExternalDocumentID | 10_1200_JCO_20_00256 32813610 |
Genre | Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: U24 CA196173 – fundername: NCI NIH HHS grantid: U10 CA180899 – fundername: NCI NIH HHS grantid: U10 CA098413 – fundername: NCI NIH HHS grantid: U10 CA180886 – fundername: NCI NIH HHS grantid: U10 CA098543 |
GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY AAYXX CITATION 5PM |
ID | FETCH-LOGICAL-c384t-ee394f10c01a9aacc413a4aa218d4ad9201b9dfa68033d17e8df3e2a9019e6b23 |
ISSN | 0732-183X |
IngestDate | Tue Sep 17 21:25:31 EDT 2024 Fri Dec 06 02:58:00 EST 2024 Tue Aug 27 13:53:14 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 28 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c384t-ee394f10c01a9aacc413a4aa218d4ad9201b9dfa68033d17e8df3e2a9019e6b23 |
Notes | K.P.D. and S.S.W. contributed equally as first authors. N.J.W., W.L.C., and S.P.H. contributed equally as senior authors. |
OpenAccessLink | https://europepmc.org/articles/pmc7526719?pdf=render |
PMID | 32813610 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7526719 crossref_primary_10_1200_JCO_20_00256 pubmed_primary_32813610 |
PublicationCentury | 2000 |
PublicationDate | 2020-10-01 |
PublicationDateYYYYMMDD | 2020-10-01 |
PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2020 |
Publisher | American Society of Clinical Oncology |
Publisher_xml | – name: American Society of Clinical Oncology |
References | B20 B21 B22 B23 B24 B25 B26 B27 B28 B29 Uckun FM (B15) 1998; 91 B30 B31 B10 B32 B11 B12 B34 B13 B14 B36 B37 B16 B38 B17 B39 B18 B19 B1 B2 B3 B4 B5 B6 B7 B9 Wood BL (B35) 2014; 124 B40 |
References_xml | – ident: B30 doi: 10.1182/blood-2003-07-2577 – ident: B24 doi: 10.1182/blood-2006-11-056754 – ident: B18 doi: 10.1016/S1470-2045(08)70314-0 – ident: B26 doi: 10.1200/JCO.2011.40.8724 – ident: B38 doi: 10.1214/aos/1176350951 – ident: B11 doi: 10.1182/blood-2011-03-338707 – ident: B36 doi: 10.1080/01621459.1958.10501452 – ident: B19 doi: 10.1200/JCO.1998.16.3.920 – ident: B25 doi: 10.1111/bjh.14877 – ident: B27 doi: 10.1002/pbc.25470 – ident: B39 doi: 10.1111/bjh.13847 – ident: B7 doi: 10.1182/blood.V124.21.3702.3702 – ident: B14 doi: 10.1016/j.blre.2017.08.006 – ident: B4 doi: 10.1056/NEJMra1400972 – ident: B21 doi: 10.1016/j.clinthera.2007.09.002 – ident: B32 doi: 10.1182/blood-2005-08-3482 – ident: B31 doi: 10.1126/science.1102160 – ident: B37 doi: 10.1038/bjc.1977.1 – ident: B20 doi: 10.1182/blood-2007-02-070342 – ident: B34 doi: 10.1111/bjh.12882 – ident: B1 doi: 10.1200/JCO.2018.77.7250 – ident: B22 doi: 10.1200/JCO.2005.03.199 – ident: B6 doi: 10.1016/S1470-2045(15)00363-0 – ident: B28 doi: 10.1038/leu.2016.60 – ident: B9 doi: 10.1016/S1470-2045(12)70600-9 – ident: B13 doi: 10.1002/(SICI)1097-0142(19980201)82:3<600::AID-CNCR24>3.0.CO;2-4 – ident: B23 doi: 10.1200/JCO.2005.03.426 – ident: B3 doi: 10.1182/blood-2015-09-670729 – volume: 91 start-page: 735 year: 1998 ident: B15 publication-title: Blood contributor: fullname: Uckun FM – ident: B40 doi: 10.1056/NEJMoa1110169 – ident: B12 doi: 10.1182/blood-2010-06-292615 – ident: B10 doi: 10.1200/JCO.2011.37.8018 – ident: B5 doi: 10.1200/JCO.2014.59.1636 – ident: B16 doi: 10.1182/blood.V99.12.4386 – ident: B2 doi: 10.1200/JCO.2015.62.4544 – ident: B29 doi: 10.1016/S0037-1963(03)00195-1 – ident: B17 doi: 10.1200/JCO.1998.16.4.1270 – volume: 124 start-page: 21 year: 2014 ident: B35 publication-title: Blood doi: 10.1182/blood.V124.21.21.21 contributor: fullname: Wood BL |
SSID | ssj0014835 |
Score | 2.6819813 |
Snippet | Nelarabine is effective in inducing remission in patients with relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) but has not been fully... |
SourceID | pubmedcentral crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 3282 |
SubjectTerms | Adolescent Antineoplastic Combined Chemotherapy Protocols - therapeutic use Arabinonucleosides - administration & dosage Arabinonucleosides - adverse effects Asparaginase - administration & dosage Asparaginase - adverse effects Child Cohort Studies Disease-Free Survival Female Humans Leucovorin - administration & dosage Leucovorin - adverse effects Male Methotrexate - administration & dosage Methotrexate - adverse effects ORIGINAL REPORTS Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Prednisone - administration & dosage Prednisone - adverse effects Treatment Outcome |
Title | Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/32813610 https://pubmed.ncbi.nlm.nih.gov/PMC7526719 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6VVqp6QVAeDS_tAXpJHZLdjR_cQgpqaEIimkq5Rev1mlglTkWcQ3riT3Dg7_FLmPXu-iFAgl4sy691NF9mZtfffIPQSypcBlGKOyGhXQd2pRN4HelEfggBMA5j4qni5NFH9-ySfZh1Zzt39iqspU0WtsTNH-tKbmNVOAZ2VVWy_2HZ4qFwAPbBvrAFC8P2n2zcN5XYlrEQrJvjVGhVJb3K1OsNh21GmS5AnywgZjUHg0HzE0-j1TK5Ueu7tjZymjfwmCrZjfQzeD-Y8_Iw0aoi4Au_bME_5rw8uGnq9NWiX08omsFwC5BYhZCHK_XXodxcyWXC_5L2FqWYK_OmlVR6bVm_54nqUwIjTlrlwlBqeohcZIqI2rwoTp1CcI90YdoIpuX8ar1IitsMpehtrkI1bFVXOWBKa_lyWaWwQHk8w2VVXBX7vuPq-2rX6VHigLOa6ShnXDvxYC6hRYGt76d-BeOmSl17ckp0UySTFVCiGzn-FnGIbqbdH7eIIgkSLZNeAd_1MkcfPK9DXUPhrcl-T0Z9r0tcT4nX7ik9R9UC4nRwXnwMY77uE2t_lKnfgJFfV8c9QPt2kFqSVWRWddZvJY2a3kN3DRBwT4P5PtqR6SHaHxmGxyE6nmgt9e0JnpalgesTfIwnpcr69gH6bsH_89uPNbbGwTnssYX9G9zDOegxgB6XoMfWqjgHPTagxyXocZLiHPS4AD3WoMc56HEN9NiC_iG6fP9u2j9zTI8RR1CfZY6UNGBxpy3aHR5wLgQkdZxxDplvxHgUQH4cBlHMXb9NadTxpB_FVBIOaXQgXXBwj9BuukrlEcKxZAICoBDS9ZmQMe9EAYPZfCQi5sWe20CvrFHm11pKZq6m4ER9T-6P50QJ9YIdG-ixNlRxlTVrA3k1ExYXKI34-pk0WeRa8QZZT25951N0UP4fn6Hd7OtGPoc8PAtf5Cj9BX484I0 |
link.rule.ids | 230,314,780,784,885,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Children%E2%80%99s+Oncology+Group+AALL0434%3A+A+Phase+III+Randomized+Clinical+Trial+Testing+Nelarabine+in+Newly+Diagnosed+T-Cell+Acute+Lymphoblastic+Leukemia&rft.jtitle=Journal+of+clinical+oncology&rft.au=Dunsmore%2C+Kimberly+P.&rft.au=Winter%2C+Stuart+S.&rft.au=Devidas%2C+Meenakshi&rft.au=Wood%2C+Brent+L.&rft.date=2020-10-01&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=38&rft.issue=28&rft.spage=3282&rft.epage=3293&rft_id=info:doi/10.1200%2FJCO.20.00256&rft_id=info%3Apmid%2F32813610&rft.externalDBID=PMC7526719 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |